Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

Fig. 4

Assessment of the effects of re-introduction of dCK into resistant cells. a Western blot analysis of dCK proteins in Z138 sub-clones, 48 h after introduction of ORF-plasmid via nucleofection. GAPDH was used as loading control. b Normalized proliferation for Z138 cells grown in cytarabine containing medium, measured by incorporation of [methyl-14C]-thymidine 48 h after introduction of ORF-plasmid via nucleofection. Each data point represents a mean value of triplicates and error bars show SD. * = p < 0.05 and ** = p < 0.01, using students unpaired t-test

Back to article page